Abstract
Despite intensive study, gaps remain in our understanding of SARS-CoV-2 transmission patterns during the COVID-19 pandemic, in part due to limited contextual metadata accompanying most large genomic surveillance datasets. We analyzed over 130,000 SARS-CoV-2 genomes, over 85,000 with matched epidemiological data, collected in Massachusetts from November 2021 to January 2023, to investigate viral transmission dynamics at high resolution. The data were drawn from diagnostic testing at >600 facilities representing schools, workplaces, public testing, and other sectors, and encompass the emergence of six major viral lineages, each representing a new outbreak. We found urban areas as key hubs for new lineage introduction and interurban transmission as facilitating spread throughout the state. Young adults, especially those on college campuses, served as early indicators of emerging lineage dominance. Resident-aged populations in college campuses and nursing homes exhibited a higher likelihood of being linked to within-facility transmission, while staff-aged at those facilities were more linked to their surrounding community. Individuals with recent vaccine doses, including boosters, had a lower likelihood of initiating transmission. This dataset shows the value of linking genomic and epidemiologic data at scale for higher resolution insights into viral dynamics and their implication for public health strategy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Samples analyzed were from CDC-funded COVID-19 diagnostic testing and genomic surveillance programs (75D30121C10501 and 75D30122C13720 to the Broad Institute Clinical Research Sequencing Platform, LLC). This work was also funded by a CDC Broad Agency Announcement (75D30120C09605 to B.L.M.), a Howard Hughes Medical Institute Investigator Award to P.C.S., the National Institute of Allergy and Infectious Diseases (U19AI110818, to P.C.S.), the Rockefeller Foundation (2021HTH013 to B.L.M. and P.C.S.), the National Human Genome Research Institute (T32HG010464-06 to G.K.M.), the National Institute of General Medical Sciences (T32GM007753 and T32GM144273 to B.P.), and the Broad MD-PhD Fellowship (to B.P.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research project (Protocol #1603078) was reviewed and approved by the Massachusetts Department of Public Health (MADPH) Institutional Review Board and covered by a reliance agreement at the Broad Institute. An additional non-human subjects research determination was made by the Harvard Longwood Campus Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
